Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

New findings from the EVEREST Phase 4 trial presented at the 2025 EAACI Congress reveal that Dupixent (dupilumab ... 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ...

“Our higher target reflects confidence in Dupilumab’s commercial COPD opportunity, adding to our already positive outlook for Regeneron on an ophthalmology franchise renewed by 8mg ...

“EVEREST is the first-ever trial to demonstrate the superiority ... In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases ...

Dupilumab is a human monoclonal antibody ... was developed by the trial sponsors (Sanofi and Regeneron Pharmaceuticals) and three of the authors. Data were collected by the investigators and ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

A pivotal phase 3 trial of dupilumab (Dupixent ... The topline results were announced in a release by Sanofi and Regeneron, which said more complete results will be presented in an upcoming ...

In the trial, Dupixent® (dupilumab) outperformed Xolair® (omalizumab ... Dupixent, which was invented using Regeneron’s proprietary VelocImmune® technology, is a fully human monoclonal ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented positive results from the EVEREST Phase 4 trial in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and ...

In the trial, Dupixent ® (dupilumab) outperformed Xolair ® (omalizumab ... Dupixent, which was invented using Regeneron's proprietary VelocImmune ® technology, is a fully human monoclonal ...